Marija Sullivan, MD

@DukeCancer Breast Medical Oncologist, via @MDAndersonNews Heme/Onc Fellowship, @OslerResidency, @HopkinsMedicine. Tweets are my own.

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

Real talk: is there a woman more generous, genius, or glamorous than Dr Mariana Chavez MacGregor? So excited for her time to help plan the @ASCO Annual Meeting. 🤩

[UT MD Anderson @UTMDAnderson]

Dr. Laura Burns Amin presented results at #ASCO26 showing pCR in triple-negative lobular breast cancer (TN-ILC) may lack the prognostic significance it has in triple-negative invasive ductal carcinoma (TN-IDC). #EndCancer

[Laura Amin, MD @Laura_B_Amin]

Feeling grateful this #ASCO26 for mentors who have shaped my career path: Drs. Chavez-MacGregor and Giordano, former co-fellows now junior faculty @inimfonjackson and @marijasullivan, and Dr. Lo, the first breast medical oncologist I worked with as a medical student.

[Marija Sullivan, MD @marijasullivan]

An inspiring Gianni Bonadonna Breast Cancer Award lecture from Dr. Sharon Giordano at #ASCO26, honoring not only her contributions to breast cancer outcomes research, but also the career journey, challenges, and moments of meaning behind the work.

@UTMDAnderson

[UT MD Anderson @UTMDAnderson]

Two researchers will be honored with @ASCO’s 2026 Special Awards: Sharon Giordano for the Gianni Bonadonna Breast Cancer Award and Eduardo Vilar-Sanchez for the ASCO-American Cancer Society Cancer Prevention Award. https://t.co/V6uwjfjB62 @shgiordano @evilarsan #ASCO26 #EndCancer

[Marija Sullivan, MD @marijasullivan]

@hoperugo @SABCSSanAntonio @OncoAlert Great work by @inimfonjackson 👏🏼

[Hope Rugo @hoperugo]

@SABCSSanAntonio Inimfon Jackson from MDACC highlights disparities in IO use and access in the US. Disparities/access is a key issue across the world - but still in the US. We need to work together for change @OncoAlert

[Marija Sullivan, MD @marijasullivan]

@inimfonjackson @Laura_B_Amin

[Marija Sullivan, MD @marijasullivan]

Reunited with @MDAndersonNews Breast Medical Oncology colleagues at #SABCS25 ✨

[Akiko Chiba, MD, FACS @chibaAkiko]

Excellent presentation by ⁦@RosenbergerMd⁩ #phyllodes expert 🌟importance of standardized path reporting, her amazing work on genomic landscape, adjuvant therapies 👇🏼👇🏼👇🏼#SABCS25 ⁦@DukeSurgOnc⁩ ⁦

[Jennifer Plichta MD (she/her) @JenniferPlichta]

@RosenbergerMd pushing #phyllodes research forward and to center stage at #SABCS25 🤩🔥🤩

[Rani Bansal, MD @DrRaniBansal]

lidERA trial shows significant improvement in IDFS and DRFI @SABCSSanAntonio !!
⭐️first adjuvant ET trial showing benefit of oral SERD over SOC ET
❗️of note did not allow for adj CDK4/6i ❓how will we incorporate that into practice?
❓Combination adj therapy? Do we need both?

[Diane Bodurka @DianeBodurka]

Congratulations to the @MDAndersonNews trainees who received 2025 @ConquerCancerFd Young Investigator and Merit Awards for their contributions to cancer research! Extremely grateful for your hard work and commitment to our mission to #EndCancer. So well-deserved!

[Inimfon Jackson @inimfonjackson]

So thankful to @ConquerCancerFd for the 2025 @ASCO YIA! I am especially grateful to my amazing mentors and to @MDAndersonNews for their unwavering support and guidance. Congrats to my fellow awardees. Proud to be a part of this inspiring group! #makingcancerhistory

[Rani Bansal, MD @DrRaniBansal]

Very exciting!!! We need new drugs especially in mTNBC and especially post topo-1 ADCs as they move further up in our treatment paradigm

[Ryan Denu, MD, PhD @RyanDenu]

@CYJiangMD is doing some impressive work on MTAP loss in bladder cancer. Come check it out. @MDAndersonNews #ASCO25 #endcancer

[UT MD Anderson @UTMDAnderson]

Dr. Marija Sullivan shared real-world insights on Oncotype DX testing and chemotherapy use in early-stage HR+ breast cancer at #ASCO25. The data show variation in testing and treatment patterns by recurrence score, age, insurance type and other clinical factors. #EndCancer @marijasullivan

[UT MD Anderson @UTMDAnderson]

At #ASCO25, Dr. Inimfon Jackson, with mentor Dr. Mariana Chavez Mac Gregor, presented data on chemotherapy declination in early-stage HR+ breast cancer. Among patients with high Oncotype DX scores, 11% declined chemotherapy despite physician recommendation. This was associated with worse overall survival. #EndCancer @inimfonjackson

[Afsaneh Amouzegar, MD @AAmouzegarMd]

Huge congratulations to my friend and @MDAndersonNews co-fellow @marijasullivan on her impactful work looking at the real-world patterns of Oncotype testing & chemo use in early-stage HR+ breast cancer #ASCO25

[Ryan Denu, MD, PhD @RyanDenu]

So proud of co-fellow @marijasullivan on a great presentation on real world implementation of Oncotype results. @MDAndersonNews #ASCO25 #endcancer